Survival From Revision Surgery for New Rigicon Infla10 Three-piece Inflatable Penile Prosthesis Is Comparable to Preceding Devices.


Journal

Urology
ISSN: 1527-9995
Titre abrégé: Urology
Pays: United States
ID NLM: 0366151

Informations de publication

Date de publication:
Oct 2023
Historique:
received: 15 04 2023
revised: 04 06 2023
accepted: 07 06 2023
medline: 23 10 2023
pubmed: 31 7 2023
entrez: 30 7 2023
Statut: ppublish

Résumé

To report the incidence of the reoperation surgeries of nearly all the Rigicon Infla10 implants performed since device introduction in 1/2019. Inflatable penile prosthesis has some of the highest survival from revision surgery of any medical device implanted in humans [1]. We expand on previous Rigicon Infla10 research, adding more patients and increasing follow-up duration [2]. 535 patients had Rigicon Infla10 devices implanted from 1/2019 to 8/2022. 103 surgeons from 26 centers in 15 countries participated in the study. Patient information forms were analyzed from virtually all implantations. Explantation or revision surgery for mechanical failure, infection, other medical reasons, and patient dissatisfaction were cataloged. SPSS 25.0 (IBM) was used for the statistical analysis of Kaplan Meier survival statistics. Mean follow-up was 24.2months (7-43months). Mean patient age was 56years. Reoperation was necessary for 3.5% of subjects. Revision for mechanical failure occurred in 2.24% (12/535). The rate of explant for patient dissatisfaction was 0.56% (3/535). Revision for component out of place was 0.37% (2/535) with an infection rate and unsuccessful Peyronie's correction being 0.19% (1/535). Survival from requiring another corrective surgery at 1, 2, and 3years was 96.4%, 95.0%, and 94.0%, respectively. These initial survival rates compare favorably to devices currently available, which have been repeatedly enhanced to improve reliability. In its first 2-3years of availability, The Rigicon Infla10 inflatable penile prosthesis shows freedom from revision comparable to existing enhanced devices that have been on the market for decades.

Identifiants

pubmed: 37517678
pii: S0090-4295(23)00641-6
doi: 10.1016/j.urology.2023.06.031
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

257-261

Informations de copyright

Published by Elsevier Inc.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: SW: International Medical Device, Rigicon, Uramix. HM: None. BK: None. GT: Rigicon. CL: Coloplast. MR: None. AC: None. MH: None. MG: Coloplast.

Auteurs

Steven K Wilson (SK)

Institute for Urologic Excellence, La Quinta, CA; Department of Urology, Dartmouth Hitchcock Medical Center, Lebanon, NH.

Hodo Haxhimolla (H)

Haximolla Urology, Canberra, Australia; Department of Urology, Dartmouth Hitchcock Medical Center, Lebanon, NH.

Boon Kua (B)

Urobriz, Wesley Hospital, Brisbane, Australia; Department of Urology, Dartmouth Hitchcock Medical Center, Lebanon, NH.

Gerard Testa (G)

Shire Urology, Sydney, Australia; Department of Urology, Dartmouth Hitchcock Medical Center, Lebanon, NH.

Christopher Love (C)

Urology South, Melbourne, Australia; Department of Urology, Dartmouth Hitchcock Medical Center, Lebanon, NH.

Mariano Rossello (M)

Instituto Medico Rossello, Palma De Majorca, Spain; Department of Urology, Dartmouth Hitchcock Medical Center, Lebanon, NH.

Alejandro Carvajal (A)

Department of Urology, CES University, Medellin, Colombia; Department of Urology, Dartmouth Hitchcock Medical Center, Lebanon, NH.

William Lynch (W)

St George Urology, Sydney, Australia; Department of Urology, Dartmouth Hitchcock Medical Center, Lebanon, NH.

Muhammed A M Hammad (MAM)

Department of Urology, University of California Irvine Health, Orange, CA; Department of Urology, Dartmouth Hitchcock Medical Center, Lebanon, NH. Electronic address: mahammad@hs.uci.edu.

Martin Gross (M)

Department of Urology, University of California Irvine Health, Orange, CA; Department of Urology, Dartmouth Hitchcock Medical Center, Lebanon, NH.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH